Lexaria Bioscience Corp. LEXXW

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
38/100
Developing

Ranked against 712 peers in Biotechnology

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. … Full LEXXW analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.71), suggesting sticky customer base.
  • Operating Leverage in Effect Operating leverage is evident (score 0.81), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 5.8th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
36
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where LEXXW ranks in Biotechnology

Lexaria Bioscience Corp. ranks #396 of 713 scored companies in Biotechnology by moat score — the top 56%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
392 Dogwood Therapeutics, Inc. DWTX 38/100 Developing
393 Jaguar Health, Inc. JAGX 38/100 Developing
394 Can-Fite Biopharma Ltd Sponsore CANF 38/100 Developing
395 Compass Therapeutics, Inc. CMPX 38/100 Developing
396 Lexaria Bioscience Corp. LEXXW 38/100 Developing
397 Abivax SA ABVX 38/100 Developing
398 Cibus, Inc. CBUS 38/100 Developing
399 MediciNova, Inc. MNOV 38/100 Developing
400 Rani Therapeutics Holdings, Inc RANI 38/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How LEXXW scores on the Corporate Default defenses

Pricing Power

Score 36 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 34 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 48 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 20 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 29 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 62 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding LEXXW's moat

What is Lexaria Bioscience Corp.'s moat score?

Lexaria Bioscience Corp. (LEXXW) scores 38 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #396 of 713 scored companies in Biotechnology, the top 56%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (62/100) and its weakest is Capital Efficiency (20/100).

How does Lexaria Bioscience Corp. compare with other Biotechnology companies?

Lexaria Bioscience Corp. ranks #396 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Compass Therapeutics, Inc. (CMPX) at 38 just above it and Abivax SA (ABVX) at 38 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Lexaria Bioscience Corp. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Lexaria Bioscience Corp.?

The Corporate Default template measures 6 defenses, and LEXXW scores: Pricing Power (36), Cost Advantage (34), Customer Stickiness (48), Capital Efficiency (20), Resilience (29), Scale & Market Position (62). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000